Multiple Myeloma (MM) is characterized by a clonal expansion of plasma cells in the bone marrow. These cells typically produce a monoclonal immunoglobulin, and its symptoms arise either from plasma cell infiltration in several organs, or secondary to the presence of a monoclonal protein peak. Symptoms ca...
Immunoglobulin light chain (AL) amyloidosis is a rare disease. Treatment is challenging, justified in part by systemic compromise and limited scientific evidence. Develop evidencebased recommendations that allow adequate treatment of patients with amyloidosis AL. A list of PICO format questions focused ...
Samaniego, Francisco;
Bull, Leonardo;
González, Néstor;
Araos, Daniel;
Rojas, Hernán;
Donoso, Javiera;
Marín, Arnaldo;
Muñiz, María Sabrina;
Castro, Ariel;
Conte, Guillermo.
BACKGROUND: The incorporation of novel drugs, such as proteasome inhibitors and immunomodulators, improved considerably the survival of patients with multiple myeloma. Aim: To evaluate the effect on survival of proteasome inhibitors and immunomodulators in patients with multiple myeloma in two national h...
Abstract BACKGROUND: In this era of target therapies, novel data on the correlation between response endpoints and survival outcomes in multiple myeloma have arisen. OBJECTIVE: To determine the impact of quality of response on clinical outcomes, using first-line treatment, and identify risk factors inf...
Introducción: el mieloma múltiple (MM) continúa siendo una enfermedad incurable sin embargo, el trasplante autólogo de médula ósea (TAH), y las drogas antineoplásicas han permitido mejorar la sobrevida global (SG) de los pacientes. Materiales y métodos: estudio de cohorte retrospectivo de 50 ...
Mieloma Múltiple,
Hospitales,
Chile,
Talidomida,
Bortezomib,
Trasplante Autólogo,
Sobrevida,
Estudios Retrospectivos,
d0335810,
Pacientes,
d0043640
Bortezomib, an inhibitor of 26S proteasome, is an anti-cancer therapeutic agent used in different cancer
types. It leads to the arrest of the cancerous cell cycle by inhibiting angiogenesis and inducing apoptosis. Liver is the vital
organ for detoxification and excretion of toxic products. The treatment ...
Crusoe, Edvan de Queiroz;
Higashi, Fabiana;
Martinez, Gracia;
Bittencourt, Rosane;
Pinto Neto, Jorge Vaz;
Sousa, Lais;
Santucci, Rodrigo;
Magalhães, Roberto José Pessoa;
Colli, Gilberto;
Nunes, Renata Ferreira Marques;
Ribeiro, Glaciano;
Nicacio, Jandir;
Zanella, Karla Richter;
Kutner, José Mauro;
Magalhaes, André;
Leão, Danielle;
Hallack Neto, Abrahão Elias;
Braga, Walter;
Souza, Emanuella G;
Guimarães, Antonio Julio A. M;
Durigon, Giovanna Steffenello;
Laks, Dani;
Maiolino, Angelo;
Hungria, Vania Tietsche de Moraes.
ABSTRACT Background: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results...
Lesión Renal Aguda/diagnóstico,
Albuminuria/etiología,
Antiinflamatorios/uso terapéutico,
Antineoplásicos/uso terapéutico,
Bortezomib/uso terapéutico,
Creatinina/sangre,
Cristalización,
Ciclofosfamida/uso terapéutico,
Dexametasona/uso terapéutico,
Diagnóstico Diferencial,
Quimioterapia Combinada,
Cadenas kappa de Inmunoglobulina/análisis,
Enfermedades Renales/diagnóstico por imagen,
Enfermedades Renales/inmunología,
Túbulos Renales Proximales/inmunología,
Túbulos Renales Proximales/ultraestructura,
Microscopía Electrónica de Transmisión/métodos,
Paraproteinemias/complicaciones,
Podocitos/inmunología,
Podocitos/patología,
Podocitos/ultraestructura,
Resultado del Tratamiento
Introducción: El mieloma múltiple (MM) es una enfermedad que va precedida por una fase previa conocida como gammapatía monoclonal de significado incierto (GMSI); en esta última existen varias anormalidades citogenéticas, que permiten la progresión a MM, entre estas encontramos reordenamientos prima...
